Comments on: Health Groups Try To Influence FDA Commish Pick http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/ News, Comment and Conversation Fri, 10 Feb 2012 18:56:03 +0000 http://wordpress.org/?v=2.6.2 By: Justice in Michigan http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385082 Justice in Michigan Fri, 19 Dec 2008 03:02:55 +0000 http://www.pharmalot.com/?p=18749#comment-385082 Re: John Mack's survey, it seems to me everyone here qualifies as a "stakeholder," but I have heard virtually no one support either Nissen or Rost [except soi-meme] (let alone Woodcock or Kessler). So this suggests there is selective bias at work, probably in both contexts. As for me, Vive Sharfstein, and even more in light of this article and in light of this news. Re: John Mack’s survey, it seems to me everyone here qualifies as a “stakeholder,” but I have heard virtually no one support either Nissen or Rost [except soi-meme] (let alone Woodcock or Kessler).

So this suggests there is selective bias at work, probably in both contexts.

As for me, Vive Sharfstein, and even more in light of this article and in light of this news.

]]> By: Tom http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385058 Tom Thu, 18 Dec 2008 23:34:08 +0000 http://www.pharmalot.com/?p=18749#comment-385058 Well, Salmon, then it's a good thing Kessler's not on the list. And it's a good thing I hadn't planned to run for the cure. Definitely a good thing I don't plan to join NAMI. Most of this list is a list of shills. Which is something I will say when I write to Tom Daschle and promote Scharfstein. Shake it up from top to bottom because it is totally corroded. Then slowly peel cowering, skilled scientists from their spots cowering in the corners up there at White Oak. "Okay to come out now." "You can do your job again." Well, Salmon, then it’s a good thing Kessler’s not on the list.

And it’s a good thing I hadn’t planned to run for the cure. Definitely a good thing I don’t plan to join NAMI.

Most of this list is a list of shills. Which is something I will say when I write to Tom Daschle and promote Scharfstein. Shake it up from top to bottom because it is totally corroded. Then slowly peel cowering, skilled scientists from their spots cowering in the corners up there at White Oak. “Okay to come out now.” “You can do your job again.”

]]> By: Salmon http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385041 Salmon Thu, 18 Dec 2008 21:12:02 +0000 http://www.pharmalot.com/?p=18749#comment-385041 You need to remember that a number of the people who have helped the FDA become what it is today came in under Kessler. Salmon You need to remember that a number of the people who have helped the FDA become what it is today came in under Kessler.

Salmon

]]> By: John Mack http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385031 John Mack Thu, 18 Dec 2008 17:56:57 +0000 http://www.pharmalot.com/?p=18749#comment-385031 Well, critics like Steve Nissen and Peter Rost are the candidates of choice in my survey of stakeholders, including executives and staffers working within the pharmaceutical industry, agents and vendors to the industry, healthcare professionals, members of the general public, and staffers within government health agencies. It is particularly interesting that former FDA Commissioner David Kessler is almost as popular as Janet Woodcock among pharmaceutical industry respondents. Perhaps it is not surprising that the drug industry favors these “insiders” and not “change agent” outsiders like Nissen, Rost, or Susan Wood, who are favored by pharma's customers: the general public and healthcare professionals. It’s just another indication that the industry may not be ready for changes that their customers want to see. You can get the complete results of the survey here: http://tinyurl.com/43o6o2 Well, critics like Steve Nissen and Peter Rost are the candidates of choice in my survey of stakeholders, including executives and staffers working within the pharmaceutical industry, agents and vendors to the industry, healthcare professionals, members of the general public, and staffers within government health agencies.

It is particularly interesting that former FDA Commissioner David Kessler is almost as popular as Janet Woodcock among pharmaceutical industry respondents.

Perhaps it is not surprising that the drug industry favors these “insiders” and not “change agent” outsiders like Nissen, Rost, or Susan Wood, who are favored by pharma’s customers: the general public and healthcare professionals.

It’s just another indication that the industry may not be ready for changes that their customers want to see.

You can get the complete results of the survey here: http://tinyurl.com/43o6o2

]]> By: OurTeam http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385027 OurTeam Thu, 18 Dec 2008 17:09:25 +0000 http://www.pharmalot.com/?p=18749#comment-385027 Shows us just how important the FDA Commish pick is going to be (in case we didn't know!). I don't think anyone in headquarters is unaware of these groups, and their various patrons. Shows us just how important the FDA Commish pick is going to be (in case we didn’t know!). I don’t think anyone in headquarters is unaware of these groups, and their various patrons.

]]> By: Pharma Res III http://www.pharmalot.com/2008/12/health-groups-try-to-influence-fda-commish-pick/#comment-385013 Pharma Res III Thu, 18 Dec 2008 13:49:22 +0000 http://www.pharmalot.com/?p=18749#comment-385013 A number of these organizations were completely created by and are captive to the pharmaceutical industry. Some may be independent but there are a few on this list that would not have existed without funding from specific pharma product groups. There is a lack of transparency here. A number of these organizations were completely created by and are captive to the pharmaceutical industry. Some may be independent but there are a few on this list that would not have existed without funding from specific pharma product groups. There is a lack of transparency here.

]]>